Effect of Acute and Chronic Administration of Methimazole on Morphine Withdrawal Signs in Adult Male Mice

authors:

avatar Mahnaz Kesmati ORCID 1 , * , avatar Khadijeh Gholami 1 , avatar S. Reza Kazeminejad 2

Department of Biology, Faculty of Sciences, Shahid Chamran University, Ahvaz, Iran
Department of Genetic, Faculty of Sciences, Shahid Chamran University, Ahvaz, Iran
Zahedan Journal of Research in Medical Sciences: Vol.17, issue 2; e1990
published online: August 21, 2013
article type: Research Article
received: May 22, 2013
accepted: June 19, 2013

How To Cite Kesmati M, Gholami K, Kazeminejad S R. Effect of Acute and Chronic Administration of Methimazole on Morphine Withdrawal Signs in Adult Male Mice. Zahedan J Res Med Sci. 2015;17(2):e1990. 

Abstract

Background:

Opioid receptors change in CNS by anti thyroid hormones drugs. In this study effect of acute and chronic methimazole (aMTZ and cMTZ) administration on morphine withdrawal were investigated.

Materials and Methods:

In this experimental study adult male mice divided into control and experimental groups receiving aMTZ or cMTZ. All groups were addicted to morphine and morphine withdrawal was induced by naloxone and jumping, rearing and climbing signs were evaluated.

Results:

Acute MTZ and chronic MTZ increased the climbing and jumping (p<0.01, p<0.001). cMTZ was more potent than the acute one.

Conclusion:

MTZ probably influences an opioid abstinence directly and/or indirectly through decrement of thyroid hormones.

Introduction

Methimazole (MTZ) as an anti thyroid drug was used to treat hyperthyroidism [1]. MTZ inhibits iodine and peroxidase from their normal interactions with thyroglobulin [2] and it causes cellular protection or cellular damage [3, 4]. Moreover, there are extra thyroidal effects of anti thyroid drugs [5]. MTZ causes cellular damage in the liver, kidney, spleen and heart and these effects are not caused by hypothyroidism itself [6]. MTZ-induced hypothyroidism has tumorigenic effects and modifies pulmonary function [7, 8].

MTZ changes amount of opioid receptors, mu, delta, and kappa, in CNS. Bhargava et al. showed that the binding of 3H-DAGO (mu receptor) to various region of rats brain, amygdala, pons, medulla, striatum, midbrain and cortex membranes in MTZ-treated rats was more than control groups, while the binding of 3H-DSTLE (delta-receptors) in amygdala and hypothalamus membranes did not change. The binding of 3H-EKC (kappa-receptors) to membranes of pons and medulla was lower but in the striatum and cortex was more than the control groups. They suggested that brain mu, delta and kappa-opioid receptors are differentially altered in hypothyroidism [9].

Morphine is an agonist for the opiate μ-receptor [10] and causes tolerance-dependency through down-regulation of μ in CNS. Physical dependency could be shown with μ-opiate antagonist’s exposure that is named withdrawal syndrome [11].

There is no evidence that show the amount of morphine dependency in presence of anti thyroid hormone drugs in acute and chronic usage. Therefore, investigation of their effects on addicted human health is necessary. Thus in the study as a first investigation effects of MTZ in acute and chronic application on morphine dependency by evaluation of its withdrawal signs were investigated.

Materials and Methods

In this experimental study adult male NMRI mice at two months of age having weights of 30-40 g obtained from animal house of Jondi-Shapour University of Medical Sciences were used. Animals were housed in plastic cages (4 per cage) in an animal room maintained at 23±1ºC on a 12 h dark cycle (light period, 07:00- 19:00). Food and water were available at all times except during experiments. Each animal was used only once and then sacrificed. Seven animals were used in each group. Body weight was recorded at the starting and on experiment days. Health condition of all animals was noted during the investigation. The whole procedure was carried out in accordance with institutional guidelines for animal care and use. MTZ purchased from Iran Hormone Company (Co), Iran. Morphine sulphate powder purchased from Tolid daru Co, Iran and naloxone from Temad Co, Iran. Morphine dependency induced by 3 daily injections of increasing morphine dose (s.c.) for 3 days (20, 40 and 80 mg/kg). In four day or testing day mice received a final morphine (40 mg/kg) and after 3 hour received naloxone (5 mg/kg, i.p.) for induction the withdrawal syndrome. Numbers of withdrawal signs such as jumping, rearing and climbing were evaluated during 30 min after naloxone injection. MTZ were injected in two ways an acute and chronic administration as followed.

Experimental procedure: Different experimental protocols were employed as following in table 1.

Table 1.

Protocol of animal treatment and investigation

InvestigationTreatmentGroups
Morphine withdrawal signs (jumping, climbing, rearing)Morphine+saline (i.p.) + naloxone (5 mg/kg, i.p.), Morphine+MTZ1 (10, 20 and 40 mg/kg, i.p.)+naloxone (5 mg/kg, i.p.)Control group Experimental group 1, 2, 3Acute application of MTZ
Morphine withdrawal signs (jumping, climbing, rearing)Tap water (24 days) +morphine +naloxone (5 mg/kg, i.p.) MTZ (500 μg/L in 24 days) * +morphine+naloxone (5 mg/kg, i.p.)Control (24 days) Experimental group (24 days)Chronic application of MTZ

1Methimazole.

*Dose selected from previous study that was induced hypothyroid disease.

Table 2.

Effects of MTZ (acute and chronic application) on morphine withdrawal signs

SignsRearingClimbingJumping
Control 127. 8±1.9924.2± 365 ± 9.65
Acute MTZ 10 mg/kg25.3±2.626.1±2.676.2±8.2
Acute MTZ 20 mg/kg26.7±1.732.4±4.1*90.8±11.2*
Acute MTZ 40 mg/kg22.2 ±4.9743.57±3.85**135.14 ±28.08**
Control 229±2.0125±2.167.14±9.33
Chronic methimazole32.57±5.6≠40.29±6.49*180.14±18.62***,≠

Value are expressed as the mean±SEM, N=7,

* p<0.05,

** p<0.01,

*** p<0.05 in compared to the control groups,

≠ p<0.001 in compared to an acute methimazole group 40,

In acute application of MTZ, animals received this drug (10, 20, 40 mg/kg, i.p.) after morphine dependency just 30 min before the naloxone or testing day. Control group received saline instead of MTZ. In chronic application of MTZ (500 μg/L in 24 days), animals received MTZ three weeks before morphine dependency and were followed to testing day.

One full feeding bottle was consumed daily. Fresh solution of MTZ was prepared daily. Control group received tap water only.

Statistical analysis: Data analyzed by SPSS-16 and all results were expressed as the mean±SEM. Statistical evaluation of data was performed using Student's t-test and analysis of variance (ANOVA) with one factor followed by Duncan test. p<0.05 was considered significant.

In the present study, all experiments and methods were carried out in accordance with the Institutional Guidelines for Animal Care and Use of Laboratory Animals, and approved by the Department of Biology of the Shahid Chamran University (Ahvaz, Iran).

Results

In acute application of MTZ only in doses of 20 and 40 mg/kg, i.p., statistically significant differences were observed between the mean number of climbing and jumping and control group with p<0.05 and p<0.01 respectively and did not change rearing behavior as it has been shown in (Table 2). Thus MTZ potentiated some of morphine withdrawal signs in dose dependent manner.

In chronic administration of MTZ, the mean number of climbing (p<0.05) and jumping (p<0.001) increased significantly compared to control group, but not rearing (Table 2). Therefore chronic application of MTZ like acute application shows potentiating effect on some of morphine withdrawal signs. Comparison between morphine withdrawal signs in acute and chronic application of MTZ showed significant difference in rearing and jumping signs (p<0.05).

Discussion

Our findings in this study as a first investigation showed that MTZ in both acute and chronic application potentiate some of the morphine withdrawal signs in addicted mice. On the other hand MTZ increases physical dependency of morphine. These results are in agreement with the idea that MTZ up regulates membranes μ-opiate receptors of amygdala, pons and medulla, striatum, midbrain and cortex [9]. It was shown that most of these regions involve in dependency of opioids [12]. Considering the similarity of MTZ effect in acute and chronic application, it seems this drug alters directly the central mechanisms of physical dependency phenomenon of morphine, because there was not enough time for thyroid hormone level changes. Although MTZ applied for hypothyroidism induction and almost total action related to hypothyroidism, some studies indicate that tissue damage found in hypothyroidism is caused by MTZ and these effects are not by hypothyroidism itself [6]. A limitation of this study is that we did not measure the thyroid hormone levels in acute and chronic application of MTZ so future studies can examine this factor separately in above mentioned phenomenon. But comparison between morphine withdrawal signs in acute and chronic application of MTZ showed a significant difference in rearing and jumping signs. It means that the chronic application of MTZ and/or MTZ-induced hypothyroidism causes more potentiating on the morphine withdrawal signs.

However according to the results of a study, hypothyroidism induces an up-regulation of endogenous opioids such as enkephalin and dynorphin mRNA in granule cells in dentate gyrus which supports our results [13].

Another study represented that hypothyroidism increases dopamine receptor sensitivity by increasing receptor concentration [14]. It has been indicated that neurotransmission of dopamine has important role in morphine withdrawal syndrome. A research team, who were studying on the condition of the morphine withdrawal syndrome, found that dopamine as a neurotransmitter plays an important role; and its agonists potentiate abstinence behaviour in rodents [15]. Based on above studies and our findings, we propose that the MTZ may affect mechanisms of morphine dependency, directly and/or indirectly, through dopamine and/or opioid receptors in addicted mice. Therefore it seems that the increasing effect of MTZ on signs of withdrawal syndrome is related to increasing of excitability or number of μ-opiate receptors.

Acknowledgements

References

  • 1.

    Zoeller RT, Crofton KM. Mode of action: developmental thyroid hormone insufficiency--neurological abnormalities resulting from exposure to propylthiouracil. Crit Rev Toxicol. 2005;35(8-9):771-81. [PubMed ID: 16417044].

  • 2.

    Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab. 2007;92(6):2157-62. [PubMed ID: 17389704]. https://doi.org/10.1210/jc.2006-2135.

  • 3.

    Tutuncu T, Demirci C, Gozalan U, Yuksek YN, Bilgihan A, Kama NA. Methimazole protects lungs during hepatic ischemia-reperfusion injury in rats: an effect not induced by hypothyroidism. J Gastroenterol Hepatol. 2007;22(5):704-9. [PubMed ID: 17444859]. https://doi.org/10.1111/j.1440-1746.2006.04202.x.

  • 4.

    Bruck R, Weiss S, Traister A, Zvibel I, Aeed H, Halpern Z, et al. Induced hypothyroidism accelerates the regression of liver fibrosis in rats. J Gastroenterol Hepatol. 2007;22(12):2189-94. [PubMed ID: 18031379]. https://doi.org/10.1111/j.1440-1746.2006.04777.x.

  • 5.

    Bandyopadhyay U, Biswas K, Banerjee RK. Extrathyroidal actions of antithyroid thionamides. Toxicol Lett. 2002;128(1-3):117-27. [PubMed ID: 11869823].

  • 6.

    Cano-Europa E, Blas-Valdivia V, Franco-Colin M, Gallardo-Casas CA, Ortiz-Butron R. Methimazole-induced hypothyroidism causes cellular damage in the spleen, heart, liver, lung and kidney. Acta Histochem. 2011;113(1):1-5. [PubMed ID: 19775732]. https://doi.org/10.1016/j.acthis.2009.07.004.

  • 7.

    Jemec B. Studies of the tumorigenic effect of two goitrogens. Cancer. 1977;40(5):2188-202. https://doi.org/10.1002/1097-0142(197711)40:5<2188::aid-cncr2820400529>3.0.co;2-o.

  • 8.

    Liu WK, Ng TB. Effect of methimazole-induced hypothyroidism on alveolar macrophages. Virchows Arch B Cell Pathol Incl Mol Pathol. 1991;60(1):21-6. [PubMed ID: 1673273].

  • 9.

    Bhargava HN, Ramarao P, Gulati A. Effect of methimazole-induced hypothyroidism on multiple opioid receptors in rat brain regions. Pharmacology. 1988;37(6):356-64. [PubMed ID: 2854273].

  • 10.

    Takemori AE, Portoghese PS. Evidence for the interaction of morphine with kappa and delta opioid receptors to induce analgesia in beta-funaltrexamine-treated mice. J Pharmacol Exp Ther. 1987;243(1):91-4. [PubMed ID: 2822908].

  • 11.

    Bhargava HN. Multiple opiate receptors of brain and spinal cord in opiate addiction. Gen Pharmacol. 1991;22(5):767-72. [PubMed ID: 1662169].

  • 12.

    Kaplan GB, Leite-Morris KA, Fan W, Young AJ, Guy MD. Opiate sensitization induces FosB/DeltaFosB expression in prefrontal cortical, striatal and amygdala brain regions. PLoS One. 2011;6(8). ee23574. [PubMed ID: 21886798]. https://doi.org/10.1371/journal.pone.0023574.

  • 13.

    Giardino L, Ceccatelli S, Hokfelt T, Calza L. Expression of enkephalin and dynorphin precursor mRNAs in brain areas of hypo-and hyperthyroid rat: effect of kainic acid injection. Brain Res. 1995;687(1-2):83-93. [PubMed ID: 7583317].

  • 14.

    Crocker AD, Overstreet DH, Crocker JM. Hypothyroidism leads to increased dopamine receptor sensitivity and concentration. Pharmacol Biochem Behav. 1986;24(6):1593-7. [PubMed ID: 3090565].

  • 15.

    Zarrindast MR, Habibi M, Borzabadi S, Fazli-Tabaei S, Hossein Yahyavi S, Rostamin P. The effects of dopamine receptor agents on naloxone-induced jumping behaviour in morphine-dependent mice. Eur J Pharmacol. 2002;451(3):287-93. [PubMed ID: 12242090].